HOOKIPA Pharma Inc. (HOOK)
Largest Insider Buys in Sector
HOOK Stock Price History Chart
HOOK Stock Performance
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Insider Activity of HOOKIPA Pharma Inc.
Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $0 and sold $0 worth of HOOKIPA Pharma Inc. stock.
On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $3.92M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.
List of Insider Buy and Sell Transactions, HOOKIPA Pharma Inc.
| 2023-08-21 | Chief Financial Officer | 7,000 0.0091% | $0.72 | $5,075 | -7.79% | |||
| 2023-08-16 | Chief Financial Officer | 8,000 0.0103% | $0.71 | $5,712 | -5.67% | |||
| 2023-07-11 | Chief Executive Officer | 5,000 0.007% | $0.83 | $4,142 | -14.57% | |||
| 2023-07-07 | Chief Executive Officer | 5,000 0.0068% | $0.81 | $4,050 | -14.50% | |||
| 2023-07-05 | Chief Executive Officer | 5,000 0.0071% | $0.89 | $4,450 | -18.79% | |||
| 2023-07-03 | Chief Executive Officer | 5,000 0.0072% | $0.89 | $4,456 | -16.94% | |||
| 2023-06-30 | Chief Financial Officer | 12,000 0.0166% | $0.88 | $10,560 | -19.15% | |||
| 2021-12-21 | Sale | Chief Medical Officer | 14,949 0.0457% | $2.49 | $37,223 | -37.90% | ||
| 2021-04-21 | Sale | 10 percent owner | 328,620 0.9448% | $11.60 | $3.81M | -58.05% | ||
| 2021-03-29 | Sale | 10 percent owner | 36,829 0.1234% | $13.67 | $503,570 | -54.96% | ||
| 2021-03-26 | Sale | 10 percent owner | 35,171 0.1167% | $13.69 | $481,642 | -54.91% | ||
| 2021-03-25 | Sale | 10 percent owner | 28,546 0.093% | $13.12 | $374,569 | -53.55% | ||
| 2021-03-24 | Sale | 10 percent owner | 52,690 0.1841% | $13.70 | $721,616 | -52.05% | ||
| 2021-03-23 | Sale | 10 percent owner | 40,000 0.1374% | $13.91 | $556,476 | -53.53% | ||
| 2021-03-22 | Sale | 10 percent owner | 40,534 0.1369% | $14.54 | $589,263 | -55.71% | ||
| 2021-03-19 | Sale | 10 percent owner | 166,230 0.5544% | $14.60 | $2.43M | -56.39% | ||
| 2020-12-17 | Sale | Chief Medical Officer | 27,979 0.1031% | $11.74 | $328,343 | -20.23% | ||
| 2020-12-16 | Sale | Chief Medical Officer | 380 0.0014% | $11.70 | $4,446 | -18.84% | ||
| 2020-10-02 | Sale | 10 percent owner | 300 0.0011% | $10.00 | $3,000 | +13.55% | ||
| 2020-09-15 | Sale | 10 percent owner | 41,597 0.1949% | $12.61 | $524,477 | +5.48% |
Insider Historical Profitability
| SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3177574 32.9111% | $2.54 | 1 | 12 | <0.0001% |
| Forbion Capital Fund II Cooperatief U.A. | 10 percent owner | 2494173 25.8329% | $2.54 | 1 | 0 | <0.0001% |
| BAKER BROS. ADVISORS LP | 820729 8.5005% | $2.54 | 1 | 0 | <0.0001% | |
| Matushansky Igor | Chief Medical Officer | 80178 0.8304% | $2.54 | 0 | 6 | |
| Aldag Jorn | Chief Executive Officer | 71952 0.7452% | $2.54 | 4 | 0 | <0.0001% |
| Kandera Reinhard | Chief Financial Officer | 43092 0.4463% | $2.54 | 3 | 0 | <0.0001% |
| Lilja Anders | Sr. VP, Technical Development | 0 0% | $2.54 | 0 | 1 | |
| Orlinger Klaus | Sr. VP, Research | 0 0% | $2.54 | 0 | 3 |
Institutional Investor Ownership
| Baker Bros Advisors LP | $5.79B | 82.14 | 8.13M | 0% | +$0 | 41.56 | |
| Artal Group S A | $4.03B | 57.27 | 5.67M | 0% | +$0 | 17.63 | |
| Tupelo Capital Management LLC | $3.93B | 55.76 | 5.52M | 0% | +$0 | 96.35 | |
| Ecor1 Capital Llc | $3.27B | 46.44 | 4.6M | 0% | +$0 | 22.96 | |
| Fidelity Investments | $2.39B | 33.94 | 3.36M | 0% | +$0 | 0.16 | |
| The Vanguard Group | $1.51B | 21.41 | 2.12M | +0.17% | +$2.57M | 0.03 | |
| Morgan Stanley | $882.93M | 12.53 | 1.24M | +4.73% | +$39.87M | 0.07 | |
| Redmile Group | $757.4M | 10.75 | 1.06M | 0% | +$0 | 7.73 | |
| Acadian Asset Management | $627,000.00 | 8.92 | 882,262 | +85.84% | +$289,622.09 | <0.01 | |
| Geode Capital Management | $473.33M | 6.72 | 664,610 | +13.49% | +$56.27M | 0.04 | |
| Ikarian Capital LLC | $377.91M | 5.36 | 530,776 | 0% | +$0 | 51.95 | |
| BlackRock | $205.98M | 2.92 | 289,293 | -1.69% | -$3.55M | <0.01 | |
| Renaissance Technologies | $156,000.00 | 2.21 | 218,446 | +15.8% | +$21,281.23 | <0.0001 | |
| Royal Bank of Canada | $150M | 2.13 | 210,297 | -4.55% | -$7.16M | 0.04 | |
| Susquehanna International Group | $127.66M | 1.81 | 179,295 | New | +$127.66M | 0.13 | |
| State Street | $114.06M | 1.62 | 160,190 | 0% | +$0 | 0.01 | |
| Northern Trust | $111.66M | 1.59 | 156,830 | +41.3% | +$32.64M | 0.02 | |
| Boothbay Fund Management LLC | $83.8M | 1.19 | 117,695 | 0% | +$0 | 2.71 | |
| Two Sigma | $67.47M | 0.96 | 94,759 | +491.65% | +$56.06M | 0.1 | |
| Bridgeway Capital Management | $62.3M | 0.88 | 87,500 | 0% | +$0 | 0.89 | |
| Prudential Financial | $45.99M | 0.65 | 64,600 | New | +$45.99M | 0.07 | |
| Xtx Topco Ltd | $43.51M | 0.62 | 61,109 | -42.22% | -$31.79M | 1.06 | |
| Tyler Stone Wealth Management | $33.57M | 0.48 | 47,150 | +21.21% | +$5.87M | 13.74 | |
| Virtu Financial Llc | $31,000.00 | 0.44 | 43,021 | New | +$31,000.00 | <0.01 | |
| Millennium Management LLC | $29.32M | 0.42 | 41,173 | -28.56% | -$11.72M | 0.02 | |
| Charles Schwab | $25.84M | 0.37 | 36,285 | 0% | +$0 | 0.01 | |
| Two Sigma Advisers LP | $25.35M | 0.36 | 35,600 | New | +$25.35M | 0.04 | |
| Hrt Financial Llc | $24,000.00 | 0.35 | 34,870 | New | +$24,000.00 | <0.0001 | |
| Jane Street Capital | $18.51M | 0.26 | 26,002 | New | +$18.51M | 0.02 | |
| Beacon Pointe Advisors Llc | $16.66M | 0.24 | 23,400 | 0% | +$0 | 0.19 | |
| Apella Capital, LLC | $16.64M | 0.2 | 19,783 | 0% | +$0 | 1.18 | |
| Group One Trading | $12.39M | 0.18 | 17,404 | 0% | +$0 | 0.16 | |
| International Assets Investment Management Llc | $10.13M | 0.14 | 14,000 | 0% | +$0 | 0.03 | |
| UBS | $8.84M | 0.13 | 12,408 | +112.43% | +$4.68M | <0.01 | |
| Tower Research Capital | $7.44M | 0.11 | 10,451 | +8.51% | +$583,831.21 | 0.07 | |
| Bank of America | $4.56M | 0.07 | 6,405 | -0.73% | -$33,468.70 | <0.0001 | |
| Advisor Group Holdings Inc | $2.85M | 0.04 | 4,000 | 0% | +$0 | 0.01 | |
| Wells Fargo | $390,000.00 | 0.01 | 548 | +1.48% | +$5,693.43 | <0.0001 | |
| Northwestern Mutual Wealth Management Co | $71,000.00 | <0.01 | 100 | New | +$71,000.00 | <0.0001 | |
| Citigroup | $53,000.00 | <0.01 | 74 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $10,000.00 | <0.01 | 14 | 0% | +$0 | <0.0001 | |
| Truvestments Capital Llc | $18,000.00 | <0.01 | 25 | New | +$18,000.00 | 0.01 |